|
KMID : 0360220230640090819
|
|
Journal of the Korean Ophthalmological Society
2023 Volume.64 No. 9 p.819 ~ p.824
|
|
|
Short-term Efficacy and Safety of Omidenepag Isopropyl 0.002% w/v Therapy for Patients with Primary Open-angle Glaucoma and Ocular Hypertension
|
|
Kim Jung-Soo
Kim Jung-Lim
|
|
|
Abstract
|
|
|
Purpose: To analyze the short-term efficacy and safety of omidenepag isopropyl 0.002% (w/v) in patients with primary open-angle glaucoma and ocular hypertension.
Methods: Data on 36 patients with primary open-angle glaucoma and ocular hypertension treated with omidenepag isopropyl 0.002% (w/v) from January 2021 to May 2022 were retrospectively analyzed. We investigated whether the drug lowered the intraocular pressure (IOP) at 1 and 3 months compared to baseline. Possible side effects were sought at each visit.
Results: The mean patient age was 59.2 years at the time of treatment. Of the 36 patients, 33 had primary open-angle
glaucoma and 3 had ocular hypertension. The baseline IOP was 15.9 ± 3.6 mmHg, which significantly decreased to 13.7 ± 2.8 and 13.4 ± 2.9 mmHg at 1 and 3 months, respectively, following instillation of omidenepag isopropyl 0.002% (w/v) (both p < 0.01). Twelve patients (29.2%) experienced side effects including hyperemia, ocular pain, and itching but only two (5.5%) stopped using the medication.
Conclusions: In the short-term, ominedepag isopropyl 0.002% (w/v) is effective and safe in patients with primary open-angle glaucoma and ocular hypertension.
|
|
|
KEYWORD
|
|
|
Hyperemia, Ocular hypertension, Omidenepag isopropyl, Primary open-angle glaucoma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|